Rational use of tocilizumab in COVID-19

Siddharth Jain¹, Shefali Khanna Sharma²

Affiliations

¹ Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India.
² Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India sharmashefali@hotmail.com.

PMID: 32737106
DOI: 10.1136/annrheumdis-2020-218519

Comment

Rational use of tocilizumab in COVID-19

Siddharth Jain et al. Ann Rheum Dis. 2022 Nov.

. 2022 Nov;81(11):e213.

doi: 10.1136/annrheumdis-2020-218519. Epub 2020 Jul 31.

Authors

Siddharth Jain¹, Shefali Khanna Sharma²

Affiliations

¹ Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India.
² Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India sharmashefali@hotmail.com.

PMID: 32737106
DOI: 10.1136/annrheumdis-2020-218519

No abstract available

Keywords: antirheumatic agents; biological therapy; communicable diseases, imported; cytokines; inflammation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment in

Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.
Potere N, Di Nisio M, Cibelli D, Scurti R, Frattari A, Porreca E, Abbate A, Parruti G. Potere N, et al. Ann Rheum Dis. 2022 Nov;81(11):e215. doi: 10.1136/annrheumdis-2020-218626. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737108 No abstract available.
Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma.
Capecchi PL, Lazzerini PE. Capecchi PL, et al. Ann Rheum Dis. 2022 Nov;81(11):e214. doi: 10.1136/annrheumdis-2020-218627. Epub 2020 Jul 31. Ann Rheum Dis. 2022. PMID: 32737112 No abstract available.

Comment on

Antirheumatic agents in covid-19: is IL-6 the right target?
Capecchi PL, Lazzerini PE, Volterrani L, Mazzei MA, Rossetti B, Zanelli G, Bennett D, Bargagli E, Franchi F, Cameli M, Valente S, Cantarini L, Frediani B. Capecchi PL, et al. Ann Rheum Dis. 2021 Jan;80(1):e2. doi: 10.1136/annrheumdis-2020-217523. Epub 2020 Apr 16. Ann Rheum Dis. 2021. PMID: 32299796 No abstract available.
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.
Potere N, Di Nisio M, Cibelli D, Scurti R, Frattari A, Porreca E, Abbate A, Parruti G. Potere N, et al. Ann Rheum Dis. 2021 Feb;80(2):1-2. doi: 10.1136/annrheumdis-2020-218243. Epub 2020 Jul 9. Ann Rheum Dis. 2021. PMID: 32647027 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Rational use of tocilizumab in COVID-19

Affiliations

Rational use of tocilizumab in COVID-19

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources